| Literature DB >> 32783915 |
Yonatan Katzenelenbogen1, Fadi Sheban1, Adam Yalin1, Ido Yofe1, Dmitry Svetlichnyy1, Diego Adhemar Jaitin1, Chamutal Bornstein1, Adi Moshe1, Hadas Keren-Shaul1, Merav Cohen1, Shuang-Yin Wang1, Baoguo Li1, Eyal David1, Tomer-Meir Salame2, Assaf Weiner3, Ido Amit4.
Abstract
Cell function and activity are regulated through integration of signaling, epigenetic, transcriptional, and metabolic pathways. Here, we introduce INs-seq, an integrated technology for massively parallel recording of single-cell RNA sequencing (scRNA-seq) and intracellular protein activity. We demonstrate the broad utility of INs-seq for discovering new immune subsets by profiling different intracellular signatures of immune signaling, transcription factor combinations, and metabolic activity. Comprehensive mapping of Arginase 1-expressing cells within tumor models, a metabolic immune signature of suppressive activity, discovers novel Arg1+ Trem2+ regulatory myeloid (Mreg) cells and identifies markers, metabolic activity, and pathways associated with these cells. Genetic ablation of Trem2 in mice inhibits accumulation of intra-tumoral Mreg cells, leading to a marked decrease in dysfunctional CD8+ T cells and reduced tumor growth. This study establishes INs-seq as a broadly applicable technology for elucidating integrated transcriptional and intra-cellular maps and identifies the molecular signature of myeloid suppressive cells in tumors.Entities:
Keywords: MDSC; Trem2; cancer immunology; fixation; immunotherapy; intracellular staining; myeloid suppressive cells; scRNA-seq; single cell genomics; tumor microenvironment
Mesh:
Substances:
Year: 2020 PMID: 32783915 DOI: 10.1016/j.cell.2020.06.032
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582